Here is the confirmation from the Annual Report. EUR250k per qtr, payable in arrears. This provides certainty of cash flow and reduces any immediate cap raise risk. Those selling now expect the price to fall due to an imminent on-market raise. CGT implications alone would require approx. 50% fall in sp to mitigate the discount applied at sale. Someone walking away with a $1m gain and no other income, will pay over $440k in tax & Medicare. 50% discount reduces it to $205,667.
- Forums
- ASX - By Stock
- 4DS
- 4DS - Anything but Charting
4DS - Anything but Charting, page-18616
-
- There are more pages in this discussion • 12,104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 4DS (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.8¢ |
Change
-0.002(2.22%) |
Mkt cap ! $155.1M |
Open | High | Low | Value | Volume |
9.0¢ | 9.1¢ | 8.8¢ | $255.0K | 2.855M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 201205 | 8.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.9¢ | 20000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 201205 | 0.088 |
8 | 774567 | 0.087 |
5 | 576804 | 0.086 |
13 | 1368456 | 0.085 |
2 | 220000 | 0.084 |
Price($) | Vol. | No. |
---|---|---|
0.089 | 20000 | 1 |
0.090 | 313381 | 2 |
0.091 | 11445 | 1 |
0.092 | 683892 | 3 |
0.093 | 181179 | 3 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
4DS (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online